BACKGROUND Inhaled corticosteroids are known to be beneficial for patients with asthma,
but their role in treating patients with stable chronic obstructive pulmonary disease (COPD) …

Introduction: Inhaled corticosteroids (ICS)(in fixed combinations with long-acting β2-agonists
[LABAs]) are frequently prescribed for patients with chronic obstructive pulmonary disease …

Systemic and local inflammation is central to the pathophysiology of chronic obstructive
pulmonary disease (COPD). Increased levels of inflammation have been linked to a more …

Inhaled corticosteroids (ICS) are the mainstay of treatment for asthma, but their role in
chronic obstructive pulmonary disease (COPD) is debated. Recent randomised controlled …

Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend limiting the use of inhaled corticosteroids (ICS) to patients with more severe …

Context Recent studies of inhaled corticosteroid (ICS) therapy for managing stable chronic
obstructive pulmonary disease (COPD) have yielded conflicting results regarding survival …

Introduction: The frequent use of inhaled corticosteroids (ICSs), especially at higher doses,
has been accompanied by concern about both systemic and local side effects. Patients …

Introduction Observational studies using case-control designs have showed an increased
risk of pneumonia associated with inhaled corticosteroid (ICS)-containing medications in …

Inhaled corticosteroid (ICS) therapy in combination with long-acting β-adrenergic agonists
represents the most important treatment for chronic airways diseases such as asthma and …

Background The widespread use of inhaled corticosteroids (ICSs) for COPD treatment has
been questioned. Recent studies of weaning some patients with COPD off ICSs found little …